Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alkahest Inc.
Headquarters: San Carlos, CA, United States of America
Website: N/A
Year Founded: 2014
Status: Acquired
BioCentury | Nov 8, 2022
Emerging Company Profile
Juvena: taking on aging with secreted proteins
Bay Area biotech is finding secreted proteins for age-related diseases systematically
BioCentury | Aug 4, 2021
Management Tracks
Arbuckle becomes COO at Vertex
Plus: GlycoMimetics names Semerjian as King’s successor, plus updates from Pieris, Assembly and more
BioCentury | May 28, 2021
Management Tracks
Lander confirmed as Biden’s science adviser and OSTP director; plus Tranquis, Herophilus and Precigen
The U.S. Senate confirmed Eric Lander, the president and founding director of the Broad Institute of MIT and Harvard, as director of the White House Office of Science and Technology Policy (OSTP).
BioCentury | Sep 9, 2020
Product Development
Sept. 8 Quick Takes: Phase III wins for Albireo, Merck and Spero; plus Corbus, Blueprint, AnHeart, Grifols-Alkahest, and Exelixis-NBE
Albireo gains on Phase III rare liver diseases readout Albireo Pharma Inc. (NASDAQ:ALBO) gained $12.25 (45%) to $39.62 on Tuesday after announcing odevixibat met its two primary endpoints in the
BioCentury | Jul 16, 2020
Emerging Company Profile
Fountain Therapeutics: an AI-based platform to reverse cellular aging
Fountain’s AI-driven platform measures cellular age as the basis for anti-aging drug screens
BioCentury | Aug 5, 2019
Clinical News
Aug. 5 Clinical Quick Takes: Emgality meets for migraine with treatment failures; plus Verona, Alkahest-Grifols, Squarex and Denali-Sanofi
BioCentury | Jul 24, 2019
Company News
July 24 Management tracks: GSK, Goldman Sachs, Ziopharm and Alkahest
BioCentury | Mar 29, 2019
Clinical News
Alkahest’s AKST4290 improves visual acuity in Phase IIa for AMD
BioCentury | Jan 26, 2019
Product Development
Raising the BD bar
Why partnering for new modalities is all about proof of mechanism
Items per page:
1 - 10 of 21